Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial.

Lærke Egefjord, Michael Gejl, Arne Møller, Hans Brændgaard, Hanne Gottrup, Olga Antropova, Niels Møller, Henrik E. Poulsen, Albert Gjedde, Birgitte Brock, Jørgen Rungby

Research output: Contribution to journalArticle

Abstract

Type 2 diabetes (DM-2) increases the risk of developing Alzheimer's disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated in the pancreas. Premature cellular degeneration is seen in both diseases. Glucagon-like peptide-1 (GLP-1) reduces the amount of Aβ and improves cognition in animal studies. The present study tests the hypothesis that treatment with the long-acting GLP-1 receptor agonist liraglutide affects the accumulation of Aβ in patients with AD. This is a randomized, controlled, double-blinded intervention study with AD patients treated for six months with liraglutide (n = 20) or placebo (n = 20). The primary outcome is change in deposition of Aβ in the central nervous system (CNS) by Pittsburgh compound B positron emission tomography (PET). The secondary outcome is evaluation of cognition using a neuro-psychological test battery, and examination of changes in glucose uptake in the CNS by 18F-fluoro-deoxy-glucose PET. Finally, a perfusion-weighted magnetic resonance imaging with contrast will be performed to evaluate blood flow. No registered drug affects the deposition of Aβ in the brain of AD patients. Our goal is to find a new therapeutic agent that alters the pathophysiology in AD patients by decreasing the formation of Aβ plaques and thereby presumably improves the cognitive function. The trial is investigator-initiated and investigator-driven and is supported by Novo Nordisk Scandinavia. ClinicalTrials.gov: NCT01469351.

Original languageEnglish (US)
JournalDanish Medical Journal
Volume59
Issue number10
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Cognition
Alzheimer Disease
Positron-Emission Tomography
Central Nervous System
Research Personnel
Islet Amyloid Polypeptide
Scandinavian and Nordic Countries
Glucose
Psychological Tests
Glucagon-Like Peptide 1
Magnetic Resonance Angiography
Brain Diseases
Liraglutide
Amyloid
Type 2 Diabetes Mellitus
Pancreas
Placebos
Brain
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial. / Egefjord, Lærke; Gejl, Michael; Møller, Arne; Brændgaard, Hans; Gottrup, Hanne; Antropova, Olga; Møller, Niels; Poulsen, Henrik E.; Gjedde, Albert; Brock, Birgitte; Rungby, Jørgen.

In: Danish Medical Journal, Vol. 59, No. 10, 10.2012.

Research output: Contribution to journalArticle

Egefjord, L, Gejl, M, Møller, A, Brændgaard, H, Gottrup, H, Antropova, O, Møller, N, Poulsen, HE, Gjedde, A, Brock, B & Rungby, J 2012, 'Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial.', Danish Medical Journal, vol. 59, no. 10.
Egefjord, Lærke ; Gejl, Michael ; Møller, Arne ; Brændgaard, Hans ; Gottrup, Hanne ; Antropova, Olga ; Møller, Niels ; Poulsen, Henrik E. ; Gjedde, Albert ; Brock, Birgitte ; Rungby, Jørgen. / Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial. In: Danish Medical Journal. 2012 ; Vol. 59, No. 10.
@article{edd00d8f686f4ca7ab6adf9de15960ba,
title = "Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial.",
abstract = "Type 2 diabetes (DM-2) increases the risk of developing Alzheimer's disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated in the pancreas. Premature cellular degeneration is seen in both diseases. Glucagon-like peptide-1 (GLP-1) reduces the amount of Aβ and improves cognition in animal studies. The present study tests the hypothesis that treatment with the long-acting GLP-1 receptor agonist liraglutide affects the accumulation of Aβ in patients with AD. This is a randomized, controlled, double-blinded intervention study with AD patients treated for six months with liraglutide (n = 20) or placebo (n = 20). The primary outcome is change in deposition of Aβ in the central nervous system (CNS) by Pittsburgh compound B positron emission tomography (PET). The secondary outcome is evaluation of cognition using a neuro-psychological test battery, and examination of changes in glucose uptake in the CNS by 18F-fluoro-deoxy-glucose PET. Finally, a perfusion-weighted magnetic resonance imaging with contrast will be performed to evaluate blood flow. No registered drug affects the deposition of Aβ in the brain of AD patients. Our goal is to find a new therapeutic agent that alters the pathophysiology in AD patients by decreasing the formation of Aβ plaques and thereby presumably improves the cognitive function. The trial is investigator-initiated and investigator-driven and is supported by Novo Nordisk Scandinavia. ClinicalTrials.gov: NCT01469351.",
author = "L{\ae}rke Egefjord and Michael Gejl and Arne M{\o}ller and Hans Br{\ae}ndgaard and Hanne Gottrup and Olga Antropova and Niels M{\o}ller and Poulsen, {Henrik E.} and Albert Gjedde and Birgitte Brock and J{\o}rgen Rungby",
year = "2012",
month = "10",
language = "English (US)",
volume = "59",
journal = "Danish Medical Journal",
issn = "2245-1919",
publisher = "Almindelige Danske Laegeforening",
number = "10",

}

TY - JOUR

T1 - Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial.

AU - Egefjord, Lærke

AU - Gejl, Michael

AU - Møller, Arne

AU - Brændgaard, Hans

AU - Gottrup, Hanne

AU - Antropova, Olga

AU - Møller, Niels

AU - Poulsen, Henrik E.

AU - Gjedde, Albert

AU - Brock, Birgitte

AU - Rungby, Jørgen

PY - 2012/10

Y1 - 2012/10

N2 - Type 2 diabetes (DM-2) increases the risk of developing Alzheimer's disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated in the pancreas. Premature cellular degeneration is seen in both diseases. Glucagon-like peptide-1 (GLP-1) reduces the amount of Aβ and improves cognition in animal studies. The present study tests the hypothesis that treatment with the long-acting GLP-1 receptor agonist liraglutide affects the accumulation of Aβ in patients with AD. This is a randomized, controlled, double-blinded intervention study with AD patients treated for six months with liraglutide (n = 20) or placebo (n = 20). The primary outcome is change in deposition of Aβ in the central nervous system (CNS) by Pittsburgh compound B positron emission tomography (PET). The secondary outcome is evaluation of cognition using a neuro-psychological test battery, and examination of changes in glucose uptake in the CNS by 18F-fluoro-deoxy-glucose PET. Finally, a perfusion-weighted magnetic resonance imaging with contrast will be performed to evaluate blood flow. No registered drug affects the deposition of Aβ in the brain of AD patients. Our goal is to find a new therapeutic agent that alters the pathophysiology in AD patients by decreasing the formation of Aβ plaques and thereby presumably improves the cognitive function. The trial is investigator-initiated and investigator-driven and is supported by Novo Nordisk Scandinavia. ClinicalTrials.gov: NCT01469351.

AB - Type 2 diabetes (DM-2) increases the risk of developing Alzheimer's disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated in the pancreas. Premature cellular degeneration is seen in both diseases. Glucagon-like peptide-1 (GLP-1) reduces the amount of Aβ and improves cognition in animal studies. The present study tests the hypothesis that treatment with the long-acting GLP-1 receptor agonist liraglutide affects the accumulation of Aβ in patients with AD. This is a randomized, controlled, double-blinded intervention study with AD patients treated for six months with liraglutide (n = 20) or placebo (n = 20). The primary outcome is change in deposition of Aβ in the central nervous system (CNS) by Pittsburgh compound B positron emission tomography (PET). The secondary outcome is evaluation of cognition using a neuro-psychological test battery, and examination of changes in glucose uptake in the CNS by 18F-fluoro-deoxy-glucose PET. Finally, a perfusion-weighted magnetic resonance imaging with contrast will be performed to evaluate blood flow. No registered drug affects the deposition of Aβ in the brain of AD patients. Our goal is to find a new therapeutic agent that alters the pathophysiology in AD patients by decreasing the formation of Aβ plaques and thereby presumably improves the cognitive function. The trial is investigator-initiated and investigator-driven and is supported by Novo Nordisk Scandinavia. ClinicalTrials.gov: NCT01469351.

UR - http://www.scopus.com/inward/record.url?scp=84877145629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877145629&partnerID=8YFLogxK

M3 - Article

VL - 59

JO - Danish Medical Journal

JF - Danish Medical Journal

SN - 2245-1919

IS - 10

ER -